FGFR3 and urothelial carcinoma: Luminal-papillary tumors, enriched for FGFR3 alterations, are sensitive to FGFR inhibitors such as erdafitinib, which has shown clinical benefit in FGFR3-mutant urothelial carcinoma [35,36].